Skip to main content
    P

    Pasithea Therapeutics Corp (KTTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.43
    -0.07 (-13.14%)

    Market Cap: $17.44M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Pasithea Therapeutics Corp (KTTA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pasithea Therapeutics (KTTA) has a market cap of $17.44M. Its share count is up 348.90% from a year earlier. It holds $41.22M more cash than debt, 236.31% of its market cap.

    Total Valuation

    Market Cap$17.44M
    Latest price (Nov 17, 2026)$0.43

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.09% in the quarter ended Sep 30, 2026 and grew 465.70% a year over 2 years.

    Shares Outstanding33.41M
    Shares Change (YoY)+348.90%
    Shares Change (QoQ)+4.09%
    Share Count Growth (2Y CAGR)+465.70%

    Valuation Ratios

    P/B Ratio0.3x
    P/TBV Ratio0.4x

    Price Statistics

    The stock is down 39.50% over 52 weeks and trades 10.42% below its 50-day average.

    Beta (1Y)1.15
    52-Week Change-39.50%
    1-Month Change+5.34%
    3-Month Change-11.37%
    6-Month Change-38.19%
    5-Year Change-99.35%
    Total Return (1Y)-39.50%
    Total Return (3Y CAGR)-58.77%
    Total Return (5Y CAGR)-61.00%
    Max Drawdown (1Y)-74.97%
    Max Drawdown (3Y)-96.80%
    Sharpe Ratio (1Y)-0.32
    Correlation with SPY (1Y)0.12
    50-Day Average$0.48
    200-Day Average$0.61
    52-Week Range$0.28 to $2.06
    RSI (14 Days)43.5
    Average Volume (20 Days)1.85M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 15.67x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio15.67x
    Quick Ratio15.67x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -56.78% over the last 12 months, against a 5-year average of -47.26%.

    Return on Equity (ROE)-56.78%
    Return on Assets (ROA)-53.42%
    ROE (5Y Average)-47.26%
    ROA (5Y Average)-43.30%
    ROIC (5Y Average)-36.71%

    Scores

    KTTA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$157.96K
    Operating Income-$27.82M
    Pretax Income-$24.83M
    Net Income-$24.83M
    Reported EPS (TTM)-$1.37

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 94.06% of the $46.49M in total assets.

    Cash and Equivalents$41.22M
    Total Debt$0
    Net Cash$41.22M
    Net Cash Per Share$1.23
    Working Capital$40.43M
    Shareholder Equity$43.73M
    Book Value Per Share$1.31
    Tangible Book Value$40.43M
    Tangible Book Per Share$1.21
    Total Assets$46.49M
    Total Liabilities$2.76M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$19.38M
    FCF Per Share-$0.58
    Depreciation and Amortization$630.16K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-40.87%
    Tangible Book Per Share Growth (2Y CAGR)-26.73%

    Revenue and profit by year

    Dividends and Yields

    KTTA does not pay a dividend.

    Buyback Yield-382.45%
    Shareholder Yield-382.45%

    Stock Splits

    The last split was a 1-for-20 reverse split on Jan 2, 2024.

    Last Split DateJan 2, 2024
    Split TypeReverse split
    Split Ratio1:20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KTTA

    What is KTTA's market cap?

    Pasithea Therapeutics has a market cap of $17.44M.

    How many shares of KTTA are outstanding?

    Pasithea Therapeutics has 33.41M shares outstanding. The count is up 348.90% from a year earlier.

    Does KTTA pay a dividend?

    No. Pasithea Therapeutics does not pay a dividend.

    How much debt does KTTA have?

    Pasithea Therapeutics has $0 of total debt and $41.22M of cash and equivalents, a net cash position of $41.22M.